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ABSTRACT
Evidence of tumor-resident mature B cell and antibody compartments and reports of associations with
favorable prognosis in malignant melanoma suggest that humoral immunity could participate in
antitumor defense. Likely striving to confer immunological protection while being subjected to tumor-
promoting immune tolerance, B cells may engender multiple functions, including antigen processing and
presentation, cytokine-mediated signaling, antibody class switching, expression and secretion. We review
key evidence in support of multifaceted immunological mechanisms by which B cells may counter or
contribute to malignant melanoma, and we discuss their potential translational implications. Dissecting
the contributions of tumor-associated humoral responses can inform future treatment avenues.
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Malignant melanoma and immune responses in the
clinical landscape
Rising incidence (global incidence reported in 2013 in 15–25
individuals in every 100,000) and the worst patient survival
rates of all skin tumors continue to make malignant melanoma
treatment clinically challenging, despite recent breakthroughs
in targeted therapies.1 Multiple moles, family history of mela-
noma and unprotected or intense exposure to UV light,2 espe-
cially UVB-induced somatic DNA mutations, such as cytidine
to thymidine (C>T) transitions,3 are among the risk factors.
Mutation of genes such as BRAF and NRAS involved in the
MAPK kinase pathway are present in more than 50% of the
melanoma tumors.4-6 Until 5 y ago, development of distant
metastases was generally associated with a historic median sur-
vival of less than one year.7 Recent breakthroughs in the under-
standing of the molecular and immunological basis of
melanoma have contributed to the development of new MAPK
pathway inhibitors, small molecule inhibitor drugs and check-
point blockade antibody treatments, improving clinical out-
comes in subsets of patients.8
Reports of tumor-resident and systemic immune responses
in melanoma patients, clinical observations of partial lesion
regressions and spontaneous remissions, increased rates of
malignant melanoma in immunosuppressed patients (organ
transplant recipients and HIV-infected individuals),9,10 as well
as partial successes of early immunostimulating treatments
such as interleukin-2 (IL-2) and interferon-a2b (IFNa-2b)
reported over many years, together support the presence of an
active immune surveillance in patients with melanoma.11,12
Investigations into the drivers of immune responses to mela-
noma elucidated not only a set of tumor-speciﬁc melanoma-
antigen-encoding gene families (MAGE, BAGE, GAGE), but
also several antigenic epitopes derived from human melanocyte
lineage-speciﬁc proteins (MART-l/Melan-A, gpl00, gp75 and
tyrosinase) recognized by CD8C and CD4C T cells.13-15 Various
peptide-based vaccination therapy approaches have been tri-
aled in patients using these antigens, often in conjunction with
cytokines, toll-like receptor (TLR) agonists and adjuvants,
some demonstrating circumscribed success.16 Evidence for a
correlation between antitumor T cell responses17-19 and height-
ened lymphocytic inﬁltrates within melanoma lesions20 with
longer patient survival have maintained interest in the search
for therapies based on counteracting peripheral tolerance. Sev-
eral personalized therapeutic approaches have been developed
for melanoma involving adoptive cell therapy (ACT) with T
cells.21-23 Some promising outcomes have been reported in
small-scale studies of patients with malignant melanoma
treated with autologous tumor-inﬁltrating lymphocyte (TIL)-
based ACT, with larger, randomized phase III clinical trials to
ascertain broader clinical beneﬁts still required.
More recently, immunotherapeutic antibodies that block
immune checkpoint molecules have led to the regulatory
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approval of the anti-cytotoxic T lymphocyte antigen-4 (CTLA-4)
antibody ipilimumab for the treatment of metastatic
melanoma,24,25 followed by the anti-programmed cell death pro-
tein 1 (PD1) receptor antibodies nivolumab and pembrolizu-
mab.26,27 These agents function through blocking inhibitory
molecules on the T cell surface, thereby counteracting immune
suppressive signals.28,29 In 2016, the FDA approved the drug ate-
zolizumab for bladder and lung cancers. Atezolizumab is an
inhibitor of the PD1 ligand (PD-L1), expressed on tumor cells
that is thought to restrict T cell activation through recognition
and engagement with PD1 on T cells.30 This has opened the way
for several phase I clinical trials currently looking at efﬁcacy of
this class of agents in patients with melanoma. The emergence of
these checkpoint inhibitor antibodies has been an important clin-
ical breakthrough, bringing cancer immunotherapy to the fore-
front of clinical oncology. Numerous reports have drawn
correlations between patient responses to checkpoint inhibitors
and the presence and nature of tumor-inﬁltrating T lymphocytes
and T cell responses to melanoma tumor antigens.31
Although insights into the roles of T cells in antitumor
responses have been widely studied and accepted as an essential
immunological dimension in anti-cancer immunity, the roles of
B cells and of the humoral response remain insufﬁciently eluci-
dated. B cells confer a broad array of functions, which include
antigen processing and presentation, cytokine-mediated signal-
ing, immune regulation, expression and secretion of antibodies.
These attributes can contribute to antitumor immunity and to
treatment responses or, on the other hand, tumors can co-opt
inhibitory immune pathways aimed at maintaining B cell
immune tolerance. The characteristics affecting these opposite
outcomes still need to be fully uncovered. Here, we review evi-
dence from human clinical investigations and from murine
cancer models in support of multifaceted immunological mecha-
nisms by which B cells may respond or contribute to melanoma.
B cells in melanoma tumor inﬂammation
B cell inﬁltration
Lymphocyte populations are found in and around many solid
tumor lesions including melanomas. While T cells are the most
prominent, inﬁltrating human B cells are increasingly being
reported in melanomas and other tumor types.32-37
In an immunohistochemical study of 106 primary human
melanoma samples, the majority of tumor tissues contained sig-
niﬁcant amounts of inﬁltrating CD20C cells, thought to be B
lymphocytes, dispersed in the stroma immediately around the
tumor.37 Denser B cell inﬁltration correlated with activated T
cells, which could imply potential activation of an antitumor
response. The percentage of both intra-tumoral and peri-
tumoral B cell inﬁltration also positively correlated with patient
survival, since patients’ samples with signiﬁcantly higher levels
of B cell inﬁltration failed to develop visceral metastasis over the
subsequent 5-y window of observation.37 In concordance, a
study following a patient cohort over 5-y since primary mela-
noma tumor resection, found that initial larger B cell inﬁltration
in primary tumors of patients positively correlated with subse-
quent improved disease-free survival after cancer vaccine ther-
apy.38 A similar correlation was found in a study on two cohorts
of 57 and 41 patients with primary cutaneous melanoma.39 An
earlier report, however, found no signiﬁcant correlation between
B cell inﬁltration and survival, although there was a signiﬁcant
association between total inﬁltrating TILs and disease progres-
sion in a cohort of 58 patients with malignant melanoma.40 A
study from a cohort of 91 patients with a clinical follow up of at
least 10 y found instead an increased tumor progression and
decreased overall survival in those patients with more than 15%
B cell density among TILs in primary cutaneous melanoma.41
Possible explanations for these discrepancies among studies
could include the different tumor locations analyzed (primary
cutaneous melanomas, distal or lymph node metastases), the
way data were analyzed (cell frequencies reported as absolute
numbers or as a proportion of TILs) and B cell detection
markers (e.g., the pan-B cell marker CD20 alone may not be suf-
ﬁcient). The latter aspect may be crucial toward building mean-
ingful correlations and a wider understanding of the B cell
subsets and their markers would probably be required.
Although these observations support the idea that the level
of B cell inﬁltration may, overall, be representative of the host’s
potential to develop antitumor responses, it remains to be
determined whether higher lymphocyte inﬁltration is a result
of a tumor antigen-speciﬁc immune response or merely recruit-
ment of lymphocytes to tumor microenvironments in response
to inﬂammation. Such contrasting ﬁndings point to a complex
relationship between humoral responses and tumors.
B cells in human melanoma-associated tertiary lymphoid
structures (TLS)
Activation of lymphocytes during adaptive immune responses
typically occurs in secondary lymphoid structures such as lymph
nodes, spleen andmucosal-associated lymphoid tissues. Chronic
inﬂammation, however, can be accompanied by the formation
of tertiary lymphoid structures (TLS) at lesion sites in both
mouse models and humans.42 These structures can vary in size
and organizational structure, from disordered mixtures of den-
dritic cells (DCs), T and B cells to highly ordered structures bear-
ing striking resemblance to germinal centers typically found in
lymphoid organs.43 TLS can be found at sites of inﬂammation in
almost any organ of the body and are thought to facilitate rapid
and robust immune responses44 (Fig. 1).
As tumor lesions bear characteristics consistent with chronic
inﬂammation, the presence of tumor-associated TLS, which
contain B cell inﬁltrates, reported in different tumor types
including melanomas, may not be surprising.37,45 In a study of
106 primary human melanoma lesions, 26% contained histo-
logically visible aggregates.37 Cipponi et al. recovered and
micro-dissected highly ordered TLS, deﬁned as lymphoid fol-
licles which contained clusters of B cells, follicular DCs, T cells
and mature DCs from 7 out of 29 human melanoma metasta-
ses.45 Sequencing of the immunoglobulin (Ig) repertoire of the
lymphoid follicles revealed clonal ampliﬁcation, isotype switch-
ing and somatic hypermutation, suggesting a local antigen-
driven response45 (Fig. 1). These hallmarks of local B cell
maturation have also been observed in immunohistochemical
analyses of extra-nodal TLS from human germ cell tumors46
and breast carcinomas.47 In an analysis of TLS in non-small
cell lung cancer, characterization of B cell subsets by
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immunohistochemistry and ﬂow cytometry detected a preva-
lence of memory B cells and plasma cells producing tumor-spe-
ciﬁc antibodies, with the density of the follicle correlating with
the number of mature plasma cells present.48 In concordance,
TLS were found to be prognostic of more favorable patient
outcomes.43,48
Collectively, these ﬁndings may indicate a role of TLS as
local sites of B cell maturation, fostering the generation of in
situ adaptive host immune responses.
Evidence for B cells and their functions in experimental
models
Murine models of melanoma and other tumors
Initial studies in murine models of melanoma and of other can-
cers suggest that B cellsmay exert both pro- and antitumor effects,
often depending on the in vivo model system. Reported tumor-
permissive properties of B cells include B cell-dependent inhibi-
tion of antitumor immunity in lymphoma and melanoma (but
not in sarcoma), through a CD40L-dependent mechanism that
affects IL-10 secretion in vitro.49 Other studies provide evidence
that B cells may support lymphangiogenesis in in vivo lymphoma
and melanoma mouse models50 and angiogenesis in vitro and
also in vivo in melanoma, bladder and lung carcinoma murine
tumor models.51 In a murine model of squamous cell carcinoma,
antitumor autoantibodies were reported to induce acute inﬂam-
mation when organized in immune complexes. According to this
study, the inﬂammatory environment regulates recruitment and
induces pro-tumoral functions of leukocytes surrounding neo-
plastic tissue through engagement of Fc gamma receptors (FcgRs)
expressed by immune cells52 (Fig. 1). These pro-tumoral func-
tions engendered by an abnormal secretion of Ig could be reversed
by administration of an anti-CD20 treatment in a combined ther-
apy with a chemotherapy agent, which ablated B cells, reprog-
rammed the chemokine expression proﬁles of macrophages and
increased CD8C T cell inﬁltration into mouse tumors.53 In con-
trast, several other studies suggest that B cells can augment T cell-
mediated antitumor responses in in vivo models of melanoma,
lymphoma, colorectal andmammary carcinoma.54-58
These in vivo studies not only suggest that B cells can
strongly contribute to tumor rejection, but also acquire
tolerant or pro-tumorigenic characteristics with disease
Figure 1. Proposed B cell functions in the melanoma tumor microenvironment. B cells may arise from the local immune surveillance environment or migrate to the tumor
from blood vessels. B cells may accumulate and expand in tumor-associated lymphoid structures (TLS), where they can encounter APCs and T cells, and undergo afﬁnity
maturation and clonal ampliﬁcation. Within the tumor, plasma cells can secrete tumor-speciﬁc IgG1 antibodies, effective in inducing ADCC, ADCP and complement-medi-
ated cytotoxicity. On the other hand, in the tumor microenvironment, B cells can be differentially activated to secrete antibody isotypes such as IgA, IgG2 and IgG4, which
may induce a weaker immune response through (a) inability to activate the complement cascade, (b) lower afﬁnities for activatory FcRs, (c) higher afﬁnities for inhibitory
FcRs, (d) lower potency in triggering ADCC and ADCP compared with IgG1 isotype antibodies and (e) in the case of IgG4, Fab-arm exchange, resulting in antibodies with
low antigenic afﬁnity. The tumor microenvironment may also differentially polarize B cells toward a regulatory phenotype (Breg) through the secretion of soluble factors
such as IL-10, which, in turn, negatively inﬂuences immune cell activation and antibody class switching.
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progression (Fig. 1). It is therefore tempting to envisage a
complex orchestration of the immune response mediated by
different B cell subsets, perhaps including B cells with
immunoregulatory properties, as is the case for different T
cell subsets.
The search for regulatory B cells (Bregs): insights from
animal models
Mizoguchi et al. ﬁrst described a subset of gut-associated
CD1d-expressing B cells that could suppress inﬂammatory pro-
gression of colitis in mice by secreting the immune regulatory
cytokine IL-10, thus coining the term “regulatory B cell”
(B10)59 (Figs. 1 and 2). In later studies, B10-like IL-10-produc-
ing B cells were reported in peripheral human blood60 and early
ﬁndings suggest that these cells may also be present in human
metastatic melanoma.61 However, possible roles of regulatory
B10-like B cells in cancer have to-date only been described in
animal models.62,63 A study in a transgenic murine model of
prostate cancer identiﬁed PD-L1 and IL-10, expressed by a sub-
population of plasma cells, as the factors responsible for CTL
inhibition after treatment with the immunogenic chemothera-
peutic drug oxaliplatin.64 Bregs have also been shown to regu-
late immunity to murine breast tumors independently of IL-10
in vivo and in vitro.65,66 Although the exact mechanism of this
IL-10-independent immune suppression is yet unknown, some
evidence links Breg activity and CD25C FoxP3C T regulatory
cell accumulation at tumor sites in murine breast tumors.66,67
Moreover, a subset of murine B220C CD19C CD25C Bregs was
shown to be enriched in 4T1 breast tumor-bearing mice and to
polarize T cells in culture toward a regulatory T cell (Treg)-like
phenotype, again in an IL-10-independent manner.65 Tumor-
derived Bregs and Tregs were consequently suggested to inter-
act with myeloid-derived suppressor cells, possibly further
potentiating Treg responses, thus amplifying immunosuppres-
sion and promoting disease progression.65 In the study of Khan
et al., Bregs expressing high levels of PD-L1 were observed to
inhibit development and expansion of follicular T helper cells
in an autoimmune disease in vivo model in mice and ex vivo in
human blood, resulting in reduced B cell maturation and T
cell-dependent humoral immune responses68 (Fig. 2).
Although pointing to potential roles for Bregs in tumor
immune escape, results obtained in animal models are yet to be
fully conﬁrmed and elucidated in the human melanoma patient
context.
B cells in melanoma immune surveillance
Evidence for reactive mature B cell responses and tumor-
speciﬁc antibodies
B cells straddle both innate and adaptive immunity, acting as
critical effectors of the humoral immune response through the
secretion of antibodies.69 In several cancer types, TILs and
peripheral B cells have the ability to produce antibodies that
could recognize autologous tumor targets, some of which have
been investigated as potential diagnostic biomarkers.70-72 The
development of the serological identiﬁcation of recombinant
expression cloning (SEREX) approach, a phage display of
cDNA libraries derived from tumor samples screened with
autologous cancer patient sera, constituted a powerful tool that
allowed the identiﬁcation of more than one hundred melanoma
antigens and autoantibodies to these. Findings from SEREX
studies supported the notion that tumors such as melanoma
are immunogenic and induce temporal tumor-reactive humoral
responses.73,74 However, whether tumor-reactive antibodies in
vivo have any antitumor protective functions remains under
debate. Mature B cells from melanoma patients were able to
produce IgG antibodies that recognize melanoma cells, and ex
vivo these antibodies could mediate tumor cell cytotoxicity75
(Fig. 2). There is also evidence of a gradual reduction of the
human B cell compartment and of tumor-reactive antibodies
with melanoma disease progression. This may indicate some
functional roles for B cells early on in the disease which may
perhaps be modulated as a part of tumor-associated immune
escape processes.76 In this regard, Oaks and colleagues
described for several human cancers an active anti-inﬂamma-
tory role of sialylated tumor-speciﬁc IgGs that may promote
tumor growth.77
Saul et al. report higher mRNA expression of mature B cell
markers in human melanoma lesions compared with normal
skin and a distinct afﬁnity-matured antibody repertoire. Anti-
bodies from melanoma lesions featured shorter complementar-
ity-determining region 3 (CDR3) sequences, clonal expansion
characteristics and differential antigen recognition patterns
(demonstrated by homology modeling), suggesting a distinct
melanoma-associated B cell response78 (Fig. 1).
Emerging evidence suggests that the state of maturation of
the B cell compartment and subsequent isotype expression of
tumor-reactive antibodies can prevent the host from mounting
an efﬁcient immune response.79 Depending on the soluble sig-
nals released in the tumor microenvironment, B cells can be
polarized to undergo class switching and express potentially
weak immune-activating antibody isotypes such as IgG480 or
IgG2 and IgA,45 as part of chronic inﬂammation and immune-
escape processes associated with human melanoma79 (Figs. 1
and 2). It is noteworthy that a subtype of murine B cells
Figure 2. Potential pro- and antitumor functions of tumor-inﬁltrating B cells.
Tumor-inﬁltrating B cells may either promote or inhibit growth and metastasis
through various immune mechanisms, involving secretion of antibodies, cytokine-
mediated activation and recruitment of other immune effector cells and engage-
ment and activation of T cells through antigen presentation via MHC in the pres-
ence of co-stimulatory molecules. Regulatory functions may be engendered
through secretion of cytokines such as IL-10, T cell inhibition by PD-L1 expression
or class switching and production of immunoglobulin isotypes with low immune
effector stimulating functions.
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(B-1 cells) have been shown to secrete IgM antibodies in a
T cell-independent manner after recognition of evolutionally
conserved structures of microbial origin through TLR in
vitro.81,82 T cell-independent and BAFF-dependent activation
has been reported to support production of IgG4 antibodies by
human B cells in autoimmune pancreatitis.83 Such innate anti-
body response triggers may also be envisaged in the context of
melanoma tumors, and may give rise to B cell expansion in the
absence of speciﬁc tumor antigen signal.
IgG4, one of the antibody isotypes produced in melano-
mas, is known to have poor immune-activating properties,
including inability to activate complement,84 a lower
capacity to mediate effector functions compared with other
isotypes85 and phagocytosis (ADCP) compared with IgG1.
These have been associated with speciﬁc structural charac-
teristics of IgG4, which determine its poor capacity to
bind C1q, its poor afﬁnity for activating receptor FcgRIIa
(known to be involved in antibody-dependent macro-
phage-mediated phagocytosis, ADCP),86 and FcgRIIIa
(crucial for NK cell-mediated ADCC functions).87 Struc-
tural characteristics of IgG4 are also responsible for rela-
tively high afﬁnity to the inhibitory Fc receptor FcgRIIb,
compared with other subclasses, and ability to undergo
Fab-arm exchange with other IgG4 molecules.88-90 Collec-
tively, through such functional attributes, IgG4 isotype
antibodies are thought to have immunomodulatory proper-
ties, and to impair antibody effector functions in can-
cer.80,91 Elevated IgG4 levels in patient circulation even in
the early stages of melanoma has been associated with dis-
ease progression and less favorable clinical outcome.80,92
IgG4C B cells and IgG4s were detected in melanoma
tumor microenvironments together with IL-10, IL-4 and
vascular endothelial growth factor (VEGF). Ex vivo co-cul-
ture experiments with human B cells and melanoma cells
suggest that melanoma cells have the ability to promote
Th2-biased conditions to support IgG4 production by B
cells.80,92 (Figs. 1 and 2).
Human melanoma lesion-resident B cells have also been
reported to express IgA class antibodies.45 IgA class switching
is normally observed in secondary lymphoid organs that drain
mucosal tissue and is associated with a tolerance induction to
commensal microbiota in the gut.93 IgA class switching is often
associated with chronic exposure to antigens and this could
facilitate a form of immune subversion mediated by the inﬂam-
matory milieu, much like that of the IgG4 class switching. IgA
is a poor inducer of complement, ADCC and ADCP.93 A study
in a murine model of prostate cancer describes a subset of
plasma cells expressing IgA in the tumor region and having
immune regulatory functions.64 Yet, more work is needed to
investigate the role human IgA response plays in tumor immu-
nity (Figs. 1 and 2).
Based on our current knowledge, it is possible that, depend-
ing on immune context and microenvironment, B cells will be
able to respond to cytokine stimuli in the presence or absence
of speciﬁc antigenic challenge, to either promote or counteract
tumor development. The tumor microenvironment could sig-
nal B cells in germinal centers and TLSs to undergo skewed
class switching, leading to the secretion of Th2-biased isotypes
and thus dampening immune response.
Could B cells act as antigen-presenting cells to enhance T
cell responses?
As professional antigen presenting cells (APC), B cells are able
to induce antigen-speciﬁc T cell priming, which requires both
recognition of antigens by their Ig-membrane bound B cell
receptor (BCR), as well as engagement of the co-stimulatory
molecule CD40 by a CD4C helper T cell. This is followed by B
cell maturation, antigen internalization, processing and presen-
tation on major histocompatibility complexes (MHC)94-98
(Fig. 2).
Depending on their activation status, B cells can also secrete
an array of cytokines, notably tumor necrosis factor-a (TNF-
a), IL-10, lymphotoxin (LT), IL-2, IL-6, IL-4 and interferon-g
(IFNg). Through cytokine secretion, B cells can exert dynamic
effects on both the local microenvironment and the systemic
immune response99-103 (Fig. 2). In allograft rejection, potent T
cell responses are a pivotal component in pathogenesis and tis-
sue destruction. Allograft tissue-reactive B cells can enhance T
cell response through antigen presentation and co-stimula-
tion.104,105 Gene-expression proﬁle studies in renal allograft
biopsies, corroborated by immunohistochemical analyses, have
shown that B cell signatures (comprising of CD20, CD74 and
Ig) are associated with acute organ rejection. Similarly, immu-
nohistochemical evaluations revealed dense interstitial CD20C
B cell aggregates in 53% (17/32) of core biopsy samples with
graft rejection.105
B cell activation may also be critical for tumor regression in
melanoma. Primary human B cells activated in vitro with
CD40 ligand and subsequently pulsed with melanoma tumor
antigens, efﬁciently processed and presented MHC class II-
restricted peptides to speciﬁc CD4C T cell clones, generating
melanoma-speciﬁc T cells.106 Ex vivo studies by Von Bergwelt-
Baildon et al. on human blood-derived lymphocytes also sug-
gest that in the context of tumor immunology, B cells have the
ability to operate as efﬁcient APCs, driving the expansion of
both memory and naive tumor-associated antigen-speciﬁc
CD4C and CD8C T cells96 (Fig. 2). B cells have also been
reported to possess direct cytotoxic killing ability against
murine 4TI breast cancer cells in a Fas/FasL-dependent manner
in the absence of IL-10107 and also in the presence of IL-2.108
B cells may thus potentially contribute a wide variety of
functions, including antigen presentation, to promote autoim-
munity or tumor rejection.
Therapeutic avenues focused on B cells
Although our understanding of the crosstalk between humoral
immunity and melanoma remains incomplete, several thera-
peutic treatments have been attempted with a view of modula
ting the B cell compartment to stimulate anticancer immunity.
The anti-CD20 monoclonal antibody (mAb) rituximab was
administered in 15 patients with renal cell carcinoma and 6
with melanoma before treatment with low doses of IL-2 in a
clinical trial, without conferring any beneﬁcial effects.109 In the
context of other tumor types, a case study of a primary cutane-
ous T cell lymphoma showed a temporary remission after a
combination therapy with rituximab and chemotherapy, asso-
ciated with decrease in Tregs and increase in CD8C T cells.110
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In a pilot study on a small cohort of nine stage IV melanoma
patients, treatment with rituximab increased the median time
without recurrences from 6 to 42 mo (no recurrence in 5 out of
9 patients at 42 mo).111 No correlation was found though
between patients with recurrences and immune cell responses.
The authors suggested that treatment beneﬁts are due to the
antibody’s ability to target a subpopulation of CD20-expressing
cancer stem cells instead. There are currently several on-going
clinical trials testing antibodies targeting CD20 for the indica-
tion of metastatic melanoma (e.g., NCT01376713,
NCT02142335; www.clinicaltrials.gov). It is the authors’ opin-
ion that, apart from anti-CD20 treatments potentially eliminat-
ing cancer stem cell populations, generally targeting a widely
expressed molecule such as CD20 does not take into account
the complex contributions of different B cell subpopulations in
cancer. Thus, more ﬁne-tuned approaches to perhaps target
speciﬁc subpopulations of B cells (e.g., regulatory or IL-10-pro-
ducing B cells) or inhibitory elements on B cells could consti-
tute possible strategies.
CD40–CD40L interactions have also been the focus of some
immunotherapies aimed at driving B cell proliferation and pro-
ducing sufﬁcient quantities of B cells in vitro for adoptive ther-
apy.112 CD40L-stimulated CD40-expressing B cells can be
expanded from small volumes of blood and have been reported
to generate antitumor CD8C T cells.113 In a preclinical setting,
adoptive transfer of B cells isolated from draining lymph nodes
of 4TI tumor-bearing mice and activated in vitro with LPS and
anti-CD40, have been shown to prevent spontaneous metastasis
of 4TI breast tumor cells to mouse lungs.114 Given encouraging
results from clinical trials and regulatory approval of the adop-
tive T cell therapy sipeleucel T for the treatment of prostate
cancer, it is tempting to consider the possibility that, in future,
activated B cells could be used as an adjuvant in adoptive T cell
therapies.
Insights from the humoral response in melanoma for
the development of future immuno-oncology
treatments
B cells play multifaceted roles in melanoma immunity through
several signaling and immunological pathways. In this review,
we showed numerous evidences supporting this concept, also
making parallels with different disease models. Yet, further
studies will be needed to dissect the mechanisms by which dif-
ferent components of B cell functions operate in melanoma,
and thus offering the potential to identify previously unappreci-
ated translational insights. Initial approaches may involve in-
depth dissection of speciﬁc B cell subsets and modulatory
markers which may affect cell differentiation, migration, func-
tions, antibody expression, maturation, class switching and
secretion. Immunologically relevant disease models and ex vivo
systems could in future also help delineate speciﬁc mechanisms
which could be responsible for immunosuppression or for acti-
vation of humoral immunity in melanoma.
As melanoma cells may be able to escape host immune
responses,115-117 the B cell repertoire and antibodies expressed
in the patient context may not be effective enough to confer
tumor clearance. Antibody isotypes such as IgG4 and IgA may
regulate immune effector functions and support immune
evasion. Melanoma-associated IgG4 could perhaps act by
restricting Fc-mediated functions of IgG therapeutic antibodies
in the circulation and in tumor lesions. These mechanisms
should be taken into consideration when designing antibody
therapeutic agents. For example, recently approved mAbs for
the treatment of melanoma target immune checkpoint mole-
cules on T cells and are designed to act through their Fab-medi-
ated effects, by removing T cell inhibitory signals. However, the
potency and mechanisms by which mAbs may also engage
immune effector cells through their Fc regions are less well
understood. Given the array of Fc receptors expressed by effec-
tor cells, including those inﬁltrating tumors, it may be impor-
tant to understand how antibodies and effector cells that form
part of tumor immune surveillance may inﬂuence antitumor
immunity, and how they affect the efﬁcacy of therapeutic anti-
bodies.118 Furthermore, it is also tempting to consider new
therapeutic opportunities through the design of therapeutic
antibodies perhaps less prone to cancer-associated immuno-
suppressive forces or those better equipped to mount effector
functions in the Th2-biased tumor microenvironment. These
may include engineered antibodies with enhanced binding to
activatory Fc receptors on immune effector cells to redirect
them against cancer, or those antibodies with Fc regions of dif-
ferent isotypes such as IgE, perhaps better able to exert immu-
nological surveillance in tissue tumors such as melanoma.119
Underpinning effective therapeutic interventions in mela-
noma will be the ability to avoid potential tumor blockade
mechanisms and enable the host to mount a robust immune
response toward a heterogeneous tumor population. In light of
encouraging advancements with the use of individual and com-
bination treatments with checkpoint blocking agents, the
potential for using B cells and the antibodies they express for
therapy or as prognostic or predictive biomarkers of treatment
responses remain largely unexplored possibilities. In future,
delineating the presence of different subsets of B cells and their
impact on immune responses against melanoma could provide
opportunities, such as targeting speciﬁc populations for elimi-
nation (e.g., Bregs or IL-10-producing B cells) or activation
(e.g., tumor antigen-speciﬁc mature memory B cells), or the use
of particular B cell subsets in adoptive therapy regimens. For
instance, studies describing checkpoint molecules such as PD-
L1 expressed by certain subsets of B cells raise the possibility to
exploit speciﬁc checkpoint inhibitors to target modulated cell
subsets as a strategy that could potentially re-kindle the antitu-
mor functions of these cells. Furthermore, designing molecules
that counteract immunosuppressive cytokines such as IL-10,
VEGF or TGF-ß from the tumor microenvironment could
revert a wider group of immune cells, including B cells, to
engage in tumor rejection. Removal of these cytokines may
allow B cells to undergo class switching to activatory antibody
isotypes (e.g., IgG1), perhaps better able to engage effector cells
against tumors. A wider immunotherapy or vaccination
approach may also aim to re-establish the antitumor functions
of different immune cell populations, to achieve simultaneous
stimulation of tumor-neutralizing CTL and humoral immune
responses against cancer antigens.
With melanoma continuing to provide the paradigm for
clinical translation of cancer treatments based on triggering the
activatory potential of T cells, more in-depth focusing on other
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immune cells including B cells and harnessing their antitumor
functions may be of key importance for the development of the
next generation of immuno-oncology agents. Dissecting B cells
and the patients’ humoral immunity and understanding how
different compartments may contribute to tumor inﬂamma-
tion, immune responses and clinical course, warrant renewed
attention and offer the possibility to widen the scope of
immune-based therapies for melanoma and other cancers.
Disclosure of potential conﬂicts of interest
No potential conﬂicts of interest were disclosed.
Funding
The research was supported by the National Institute for Health Research
(NIHR) BRC based at Guy’s and St. Thomas’ NHS Foundation Trust and
King’s College London. The views expressed are those of the author(s) and
not necessarily those of the NHS, the NIHR or the Department of Health.
The authors acknowledge support by the Medical Research Council (MR/
L023091/1); The British Skin Foundation (S633); The Dermatrust; Guy’s
and St. Thomas’s Charity Melanoma Special Fund; Cancer Research UK
(C30122/A11527; C30122/A15774); the Academy of Medical Sciences; CR
UK/EPSRC/MRC/NIHR KCL/UCL Comprehensive Cancer Imaging Cen-
tre (C1519/A10331); Breakthrough Breast Cancer/Breast Cancer Now
(147); CR UK/NIHR in England/DoH for Scotland, Wales and Northern
Ireland Experimental Cancer Medicine Centre (C10355/A15587).
ORCID
Giulia Chiaruttini http://orcid.org/0000-0002-2548-3307
Sophia N. Karagiannis http://orcid.org/0000-0002-4100-7810
References
1. Schadendorf , Hauschild A. Melanoma in 2013: Melanoma-the run of
success continues. Nat Rev Clin Oncol 2014; 11:75-6; PMID:24419300;
http://dx.doi.org/10.1038/nrclinonc.2013.246
2. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. The Lan-
cet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/
S0140-6736(13)60802-8
3. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat
JP, Nickerson E, Auclair D, Li L, Place C et al. A landscape of driver
mutations in melanoma. Cell 2012; 150:251-63; PMID:22817889;
http://dx.doi.org/10.1016/j.cell.2012.06.024
4. Cancer Genome Atlas Network. Genomic classiﬁcation of cutaneous
melanoma. Cell 2015; 161:1681-96; PMID:26091043; http://dx.doi.
org/10.1016/j.cell.2015.05.044
5. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J.
Screening of N-ras codon 61 mutations in paired primary and meta-
static cutaneous melanomas: mutations occur early and persist
throughout tumor progression. Clin Cancer Res 2002; 8:3468-74;
PMID:12429636
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague
J, Woffendin H, Garnett MJ, Bottomley W et al. Mutations of the
BRAF gene in human cancer. Nature 2002; 417:949-54;
PMID:12068308; http://dx.doi.org/10.1038/nature00766
7. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Sys-
tematic review of medical treatment in melanoma: current status
and future prospects. Oncologist 2011; 16:5-24; PMID:21212434;
http://dx.doi.org/10.1634/theoncologist.2010-0190
8. Ugurel S, R€ohmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A,
Larkin J, Long GV, Lorigan P, McArthur GA et al. Survival of
patients with advanced metastatic melanoma: The impact of novel
therapies. Eur J Cancer 2016; 53:125-34; PMID:26707829; http://dx.
doi.org/10.1016/j.ejca.2015.09.013
9. Robbins HA, Clarke CA, Arron ST, Tatalovich Z, Kahn AR, Hernan-
dez BY, Paddock L, Yanik EL, Lynch CF, Kasiske BL et al. Melanoma
risk and survival among organ transplant recipients. J Invest Derma-
tol 2015; 135:2657-65; PMID:26270022; http://dx.doi.org/10.1038/
jid.2015.312
10. Shiels MS, Copeland G, Goodman MT, Harrell J, Lynch CF, Pawlish
K, Pfeiffer RM, Engels EA. Cancer stage at diagnosis in patients
infected with the human immunodeﬁciency virus and transplant
recipients. Cancer 2015; 121:2063-71; PMID:25739496; http://dx.doi.
org/10.1002/cncr.29324
11. Mocellin S, Lens MB, Pasquali S, Pilati P, Chiarion Sileni V. Inter-
feron alpha for the adjuvant treatment of cutaneous melanoma.
Cochrane Database Syst Rev 2013; Issue 6. Art. No.:CD008955;
PMID:23775773; http://dx.doi.org/10.1002/14651858.CD008955.
pub2
12. Gaffen SL, Liu KD. Overview of interleukin-2 function, production
and clinical applications. Cytokine 2004; 28:109-23;
PMID:15473953; http://dx.doi.org/10.1016/j.cyto.2004.06.010
13. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette
A, Rosenberg SA, Robbins PF. Melanoma-speciﬁc CD4C T cells rec-
ognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp
Med 1996; 183:1965-71; PMID:8642306; http://dx.doi.org/10.1084/
jem.183.5.1965
14. Cole DJ, Weil DP, Shamamian P, Rivoltini L, Kawakami Y, Topalian
S, Jennings C, Eliyahu S, Rosenberg SA, Nishimura MI. Identiﬁcation
of MART-1-speciﬁc T-cell receptors: T cells utilizing distinct T-cell
receptor variable and joining regions recognize the same tumor epi-
tope. Cancer Res 1994; 54:5265-8; PMID:7522957
15. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yan-
nelli JR, Appella E, Rosenberg SA. Identiﬁcation of the immunodo-
minant peptides of the MART-1 human melanoma antigen
recognized by the majority of HLA-A2-restricted tumor inﬁltrating
lymphocytes. J Exp Med 1994; 180:347-52; PMID:7516411; http://dx.
doi.org/10.1084/jem.180.1.347
16. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving
beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416;
http://dx.doi.org/10.1038/nm1100
17. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich
JR, Mixon A, Farid S, Dudley ME et al. PD-1 identiﬁes the patient-
speciﬁc CD8C tumor-reactive repertoire inﬁltrating human tumors. J
Clin Invest 2014; 124:2246-59; PMID:24667641; http://dx.doi.org/
10.1172/JCI73639
18. Bronte V, Kasic T, Gri G, Gallana K, Borsellino G, Marigo I, Battis-
tini L, Iafrate M, Prayer-Galetti T, Pagano F et al. Boosting antitumor
responses of T lymphocytes inﬁltrating human prostate cancers. J
Exp Med 2005; 201:1257-68; PMID:15824085; http://dx.doi.org/
10.1084/jem.20042028
19. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans
J, Hemmi S, Hengartner H, Zinkernagel RM. Roles of tumour locali-
zation, second signals and cross priming in cytotoxic T-cell induc-
tion. Nature 2001; 411:1058-64; PMID:11429607; http://dx.doi.org/
10.1038/35082583
20. Clemente CG, Mihm MC, Bufalino R, Zurrida S, Collini P, Cascinelli
N. Prognostic value of tumor inﬁltrating lymphocytes in the vertical
growth phase of primary cutaneous melanoma. Cancer 1996;
77:1303-10; PMID:8608507; http://dx.doi.org/10.1002/(SICI)1097-
0142(19960401)77:7%3c1303::AID-CNCR12%3e3.0.CO;2-5
21. Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P,
Radvanyi L. Tumor-inﬁltrating lymphocyte therapy for melanoma:
rationale and issues for further clinical development. BioDrugs 2014;
28:421-37; PMID:24890028; http://dx.doi.org/10.1007/s40259-014-
0097-y
22. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized
immunotherapy for human cancer. Science 2015; 348:62-8;
PMID:25838374; http://dx.doi.org/10.1126/science.aaa4967
23. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK,
Muranski P, Restifo NP, Antony PA. Naive tumor-speciﬁc CD4
(C) T cells differentiated in vivo eradicate established melanoma.
J Exp Med 2010; 207:651-67; PMID:20156973; http://dx.doi.org/
10.1084/jem.20091921
ONCOIMMUNOLOGY e1294296-7
24. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen
JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved
survival with ipilimumab in patients with metastatic melanoma. N
Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/
10.1056/NEJMoa1003466
25. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White
DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipili-
mumab: long-term follow-up of 177 patients with metastatic mela-
noma. Clin Cancer Res 2012; 18:2039-47; PMID:22271879; http://dx.
doi.org/10.1158/1078-0432.CCR-11-1823
26. Del Vecchio M. [AACR update on 5-year survival rates, efﬁcacy and
long-term safety in previously treated advanced/metastatic mela-
noma patients receiving mono-immunotherapy with nivolumab].
Recenti Prog Med 2016; 107:414-7; PMID:27571556
27. Burns MC, O’Donnell A, Puzanov I. Pembrolizumab for the
treatment of advanced melanoma. Expert Opin Orphan Drugs
2016; 4:867-73; PMID:27597930; http://dx.doi.org/10.1080/
21678707.2016.1191348
28. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade
reverses the suppression of melanoma antigen-speciﬁc CTL by
CD4C CD25(Hi) regulatory T cells. Int Immunol 2009; 21:1065-77;
PMID:19651643; http://dx.doi.org/10.1093/intimm/dxp072
29. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory Path-
ways in the B7-CD28 Ligand-Receptor Family. Immunity 2016; 44:955-
72;PMID:27192563;http://dx.doi.org/10.1016/j.immuni.2016.05.002
30. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the
B7 family, co-stimulates T-cell proliferation and interleukin-10
secretion. Nat Med 1999; 5:1365-9; PMID:10581077; http://dx.doi.
org/10.1038/70932
31. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert
L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al. PD-1 block-
ade induces responses by inhibiting adaptive immune resistance.
Nature 2014; 515:568-71; PMID:25428505; http://dx.doi.org/
10.1038/nature13954
32. Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M,
Koura K, Kanomata N, Kawaguchi A, Akiba J, Naito Y et al.
Tumor-inﬁltrating lymphocytes are important pathologic predic-
tors for neoadjuvant chemotherapy in patients with breast can-
cer. Hum Pathol 2012; 43:1688-94; PMID:22516244; http://dx.
doi.org/10.1016/j.humpath.2011.12.013
33. Woo JR, Liss MA, Muldong MT, Palazzi K, Strasner A, Ammirante
M, Varki N, Shabaik A, Howell S, Kane CJ et al. Tumor inﬁltrating
B-cells are increased in prostate cancer tissue. J Transl Med 2014;
12:30; PMID:24475900; http://dx.doi.org/10.1186/1479-5876-12-30
34. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH,
Nelson BH. CD20C tumor-inﬁltrating lymphocytes have an atypical
CD27- memory phenotype and together with CD8C T cells promote
favorable prognosis in ovarian cancer. Clin Cancer Res 2012;
18:3281-92; PMID:22553348; http://dx.doi.org/10.1158/1078-0432.
CCR-12-0234
35. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Four-
nie JJ, Rochaix P, Girard JP. Human solid tumors contain high
endothelial venules: association with T- and B-lymphocyte inﬁl-
tration and favorable prognosis in breast cancer. Cancer Res
2011; 71:5678-87; PMID:21846823; http://dx.doi.org/10.1158/
0008-5472.CAN-11-0431
36. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf
AC, Angell H, Fredriksen T, Lafontaine L, Berger A et al. Spatiotem-
poral dynamics of intratumoral immune cells reveal the immune
landscape in human cancer. Immunity 2013; 39:782-95;
PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
37. Ladanyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fej€os Z,
Gaudi I, Dobos J, Tımar J. Prognostic impact of B-cell density in
cutaneous melanoma. Cancer Immunol Immunother 2011; 60:1729-
38; PMID:21779876; http://dx.doi.org/10.1007/s00262-011-1071-x
38. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Den-
gel LT, Patterson JW, Slingluff CL. Immunotype and immuno-
histologic characteristics of tumor-inﬁltrating immune cells are
associated with clinical outcome in metastatic melanoma. Cancer
Res 2012; 72:1070-80; PMID:22266112; http://dx.doi.org/10.1158/
0008-5472.CAN-11-3218
39. Garg K, Maurer M, Griss J, Br€uggen MC, Wolf IH, Wagner C, Willi
N, Mertz KD, Wagner SN. Tumor-associated B cells in cutaneous
primary melanoma and improved clinical outcome. Hum Pathol
2016; 54:157-64; PMID:27107457; http://dx.doi.org/10.1016/j.
humpath.2016.03.022
40. Hussein MR, Elsers DA, Fadel SA, Omar AE. Immunohistological
characterisation of tumour inﬁltrating lymphocytes in melanocytic
skin lesions. J Clin Pathol 2006; 59:316-24; PMID:16505286; http://
dx.doi.org/10.1136/jcp.2005.028860
41. Martinez-Rodriguez M, Thompson AK, Monteagudo C. A signiﬁcant
percentage of CD20-positive TILs correlates with poor prognosis in
patients with primary cutaneous malignant melanoma. Histopathol-
ogy 2014; 65:726-8; PMID:24750176; http://dx.doi.org/10.1111/
his.12437
42. Jones GW, Hill DG, Jones SA. Understanding Immune Cells in Ter-
tiary Lymphoid Organ Development: It Is All Starting to Come
Together. Front Immunol 2016; 7:401; PMID:27752256; http://dx.
doi.org/10.3389/ﬁmmu.2016.00401
43. Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary lymphoid struc-
ture-associated B cells are key players in anti-tumor immunity. Front
Immunol 2015; 6:67; PMID:25755654; http://dx.doi.org/10.3389/
ﬁmmu.2015.00067
44. Silin¸a K, Rulle U, Kalnin¸a Z, Line A. Manipulation of tumour-inﬁl-
trating B cells and tertiary lymphoid structures: a novel anti-cancer
treatment avenue? Cancer Immunol Immunother 2014; 63:643-62;
PMID:24695950; http://dx.doi.org/10.1007/s00262-014-1544-9
45. Cipponi A, Mercier M, Seremet T, Baurain JF, Theate I, van den
Oord J, Stas M, Boon T, Coulie PG, van Baren N. Neogenesis of lym-
phoid structures and antibody responses occur in human melanoma
metastases. Cancer Res 2012; 72:3997-4007; PMID:22850419; http://
dx.doi.org/10.1158/0008-5472.CAN-12-1377
46. Willis SN, Mallozzi SS, Rodig SJ, Cronk KM, McArdel SL, Caron T,
Pinkus GS, Lovato L, Shampain KL, Anderson DE et al. The micro-
environment of germ cell tumors harbors a prominent antigen-
driven humoral response. J Immunol 2009; 182:3310-7;
PMID:19234230; http://dx.doi.org/10.4049/jimmunol.0803424
47. Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green
AR. The prognostic signiﬁcance of B lymphocytes in invasive carci-
noma of the breast. Breast Cancer Res Treat 2012; 132:545-53;
PMID:21671016; http://dx.doi.org/10.1007/s10549-011-1620-1
48. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc
J, Lepelley A, Becht E, Katsahian S, Bizouard G et al. Presence
of B cells in tertiary lymphoid structures is associated with a
protective immunity in patients with lung cancer. Am J Respir
Crit Care Med 2014; 189:832-44; PMID:24484236; http://dx.doi.
org/10.1164/rccm.201309-1611OC
49. Inoue S, Leitner WW, Golding B, Scott D. Inhibitory effects of B cells
on antitumor immunity. Cancer Res 2006; 66:7741-7;
PMID:16885377; http://dx.doi.org/10.1158/0008-5472.CAN-05-3766
50. Ruddell A, Harrell MI, Furuya M, Kirschbaum SB, Iritani BM. B
lymphocytes promote lymphogenous metastasis of lymphoma and
melanoma. Neoplasia 2011; 13:748-57; PMID:21847366; http://dx.
doi.org/10.1593/neo.11756
51. Yang C, Lee H, Pal S, Jove V, Deng J, Zhang W, Hoon DS, Waka-
bayashi M, Forman S, Yu H. B cells promote tumor progression via
STAT3 regulated-angiogenesis. PLoS One 2013; 8:e64159;
PMID:23734190; http://dx.doi.org/10.1371/journal.pone.0064159
52. Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S,
Korets L, Lam J, Tawﬁk D, DeNardo DG et al. FcRgamma activation
regulates inﬂammation-associated squamous carcinogenesis. Cancer
Cell 2010; 17:121-34; PMID:20138013; http://dx.doi.org/10.1016/j.
ccr.2009.12.019
53. Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Born-
stein S, Bergsland E, Steinhoff M, Li Y, Gong Q et al. B cells regulate
macrophage phenotype and response to chemotherapy in squamous
carcinomas. Cancer Cell 2014; 25:809-21; PMID:24909985; http://dx.
doi.org/10.1016/j.ccr.2014.04.026
e1294296-8 G. CHIARUTTINI ET AL.
54. DiLillo DJ, Yanaba K, Tedder TF. B cells are required for opti-
mal CD4C and CD8C T cell tumor immunity: therapeutic B cell
depletion enhances B16 melanoma growth in mice. J Immunol
2010; 184:4006-16; PMID:20194720; http://dx.doi.org/10.4049/
jimmunol.0903009
55. Kobayashi T, Hamaguchi Y, Hasegawa M, Fujimoto M, Takehara K,
Matsushita T. B cells promote tumor immunity against B16F10 mel-
anoma. Am J Pathol 2014; 184:3120-9; PMID:25173132; http://dx.
doi.org/10.1016/j.ajpath.2014.07.003
56. Zhou P, Qiu J, L’Italien L, Gu D, Hodges D, Chao CC, Schebye XM.
Mature B cells are critical to T-cell-mediated tumor immunity
induced by an agonist anti-GITR monoclonal antibody. J Immun-
other 2010; 33:789-97; PMID:20842058; http://dx.doi.org/10.1097/
CJI.0b013e3181ee6ba9
57. Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maio-
lino P, Arra C, Cicala C, Pinto A, Morello S. Inhibition of CD73
improves B cell-mediated anti-tumor immunity in a mouse model of
melanoma. J Immunol 2012; 189:2226-33; PMID:22826317; http://
dx.doi.org/10.4049/jimmunol.1200744
58. Wennhold K, Weber TM, Thelen M, Garcia-Marquez M, Chakupur-
akal G, Klein-Gonzalez N, Fiedler A, Schl€osser HA, Fischer R, Theur-
ich S et al. CD40-activated B cells induce anti-tumor immunity in
vivo. Oncotarget 2016 Feb 25; PMID:26934557; http://dx.doi.org/
10.18632/oncotarget.7720
59. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK.
Chronic intestinal inﬂammatory condition generates IL-10-produc-
ing regulatory B cell subset characterized by CD1d upregulation.
Immunity 2002; 16:219-30; PMID:11869683; http://dx.doi.org/
10.1016/S1074-7613(02)00274-1
60. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi
GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD et al.
Characterization of a rare IL-10-competent B-cell subset in humans
that parallels mouse regulatory B10 cells. Blood 2011; 117:530-41;
PMID:20962324; http://dx.doi.org/10.1182/blood-2010-07-294249
61. Egbuniwe I, Mohamad MH, Karagiannis SN, Nestle FO, Lacy KE.
Interleukin-10-producing B-cell populations in melanoma. Br J Der-
mat 2012; 166, No. 4, P-21, 04.2012, p. e35
62. Ganti SN, Albershardt TC, Iritani BM, Ruddell A. Regulatory B cells
preferentially accumulate in tumor-draining lymph nodes and pro-
mote tumor growth. Sci Rep 2015; 5:12255; PMID:26193241; http://
dx.doi.org/10.1038/srep12255
63. Zhang Y, Gallastegui N, Rosenblatt JD. Regulatory B cells in anti-
tumor immunity. Int Immunol 2015; 27:521-30; PMID:25999597;
http://dx.doi.org/10.1093/intimm/dxv034
64. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E,
Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE et al.
Immunosuppressive plasma cells impede T-cell-dependent immuno-
genic chemotherapy. Nature 2015; 521:94-8; PMID:25924065; http://
dx.doi.org/10.1038/nature14395
65. Olkhanud PB, Damdinsuren B, Bodogai M, Gress RE, Sen R,
Wejksza K, Malchinkhuu E, Wersto RP, Biragyn A. Tumor-evoked
regulatory B cells promote breast cancer metastasis by converting
resting CD4C T cells to T-regulatory cells. Cancer Res 2011; 71:3505-
15; PMID:21444674; http://dx.doi.org/10.1158/0008-5472.CAN-10-
4316
66. Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T,
Rosenblatt JD. B lymphocyte inhibition of anti-tumor response
depends on expansion of Treg but is independent of B-cell IL-10
secretion. Cancer Immunol Immunother 2013; 62:87-99;
PMID:22772949; http://dx.doi.org/10.1007/s00262-012-1313-6
67. Tadmor T, Zhang Y, Cho HM, Podack ER, Rosenblatt JD. The
absence of B lymphocytes reduces the number and function of T-reg-
ulatory cells and enhances the anti-tumor response in a murine
tumor model. Cancer Immunol Immunother 2011; 60:609-19;
PMID:21253724; http://dx.doi.org/10.1007/s00262-011-0972-z
68. Khan AR, Hams E, Floudas A, Sparwasser T, Weaver CT, Fallon PG.
PD-L1hi B cells are critical regulators of humoral immunity. Nat
Commun 2015; 6:5997; PMID:25609381; http://dx.doi.org/10.1038/
ncomms6997
69. LeBien TW, Tedder TF. B lymphocytes: how they develop and func-
tion. Blood 2008; 112:1570-80; PMID:18725575; http://dx.doi.org/
10.1182/blood-2008-02-078071
70. Chen H, Werner S, Butt J, Z€ornig I, Knebel P, Michel A, Eichm€uller
SB, J€ager D, Waterboer T, Pawlita M et al. Prospective evaluation of
64 serum autoantibodies as biomarkers for early detection of colorec-
tal cancer in a true screening setting. Oncotarget 2016; 7:16420-32;
PMID:26909861; http://dx.doi.org/10.18632/oncotarget.7500
71. Dumstrei K, Chen H, Brenner H. A systematic review of serum auto-
antibodies as biomarkers for pancreatic cancer detection. Oncotarget
2016; 7:11151-64; PMID:26840568
72. Katayama H, Boldt C, Ladd JJ, Johnson MM, Chao T, Capello M, Suo
J, Mao J, Manson JE, Prentice R et al. An autoimmune response sig-
nature associated with the development of triple-negative breast can-
cer reﬂects disease pathogenesis. Cancer Res 2015; 75:3246-54;
PMID:26088128; http://dx.doi.org/10.1158/0008-5472.CAN-15-0248
73. Sahin U, T€ureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R,
Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms
elicit multiple speciﬁc immune responses in the autologous host.
Proc Natl Acad Sci U S A 1995; 92:11810-3; PMID:8524854; http://
dx.doi.org/10.1073/pnas.92.25.11810
74. Pfreundschuh M. The genealogy of SEREX. Cancer Immun 2012;
12:7; PMID:22896752
75. Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH,
Takhar P, Geh JL, Healy C, Harries M et al. Monitoring the systemic
human memory B cell compartment of melanoma patients for anti-
tumor IgG antibodies. PLoS One 2011; 6:e19330; PMID:21559411;
http://dx.doi.org/10.1371/journal.pone.0019330
76. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld
MR, Kaplan DE, Chang KM, Domchek SM, Kanetsky PA et al. Col-
lapse of the CD27C B-cell compartment associated with systemic
plasmacytosis in patients with advanced melanoma and other can-
cers. Clin Cancer Res 2009; 15:4277-87; PMID:19549767; http://dx.
doi.org/10.1158/1078-0432.CCR-09-0537
77. Oaks M, Taylor S, Shaffer J. Autoantibodies targeting tumor-associ-
ated antigens in metastatic cancer: Sialylated IgGs as candidate anti-
inﬂammatory antibodies. Oncoimmunology 2013; 2:e24841;
PMID:23894724; http://dx.doi.org/10.4161/onci.24841
78. Saul L, Ilieva KM, Bax HJ, Karagiannis P, Correa I, Rodriguez-Her-
nandez I, Josephs DH, Tosi I, Egbuniwe IU, Lombardi S et al. IgG
subclass switching and clonal expansion in cutaneous melanoma and
normal skin. Sci Rep 2016; 6:29736; PMID:27411958; http://dx.doi.
org/10.1038/srep29736
79. Karagiannis P, Gilbert AE, Nestle FO, Karagiannis SN. IgG4 antibod-
ies and cancer-associated inﬂammation: Insights into a novel mecha-
nism of immune escape. Oncoimmunology 2013; 2:e24889;
PMID:24073371; http://dx.doi.org/10.4161/onci.24889
80. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Cor-
rea I, Roberts L, Beddowes E, Koers A et al. IgG4 subclass antibodies
impair antitumor immunity in melanoma. J Clin Invest 2013;
123:1457-74; PMID:23454746; http://dx.doi.org/10.1172/JCI65579
81. Egbuniwe IU, Karagiannis SN, Nestle FO, Lacy KE. Revisiting the role
of B cells in skin immune surveillance. Trends Immunol 2015; 36:102-
11; PMID:25616715; http://dx.doi.org/10.1016/j.it.2014.12.006
82. Baumgarth N. The double life of a B-1 cell: self-reactivity selects for
protective effector functions. Nat Rev Immunol 2011; 11:34-46;
PMID:21151033; http://dx.doi.org/10.1038/nri2901
83. Watanabe T, Yamashita K, Fujikawa S, Sakurai T, Kudo M, Shiokawa
M, Kodama Y, Uchida K, Okazaki K, Chiba T. Involvement of activa-
tion of toll-like receptors and nucleotide-binding oligomerization
domain-like receptors in enhanced IgG4 responses in autoimmune
pancreatitis. Arthritis Rheum 2012; 64:914-24; PMID:21971969;
http://dx.doi.org/10.1002/art.33386
84. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K,
Satoh M, Shitara K. IgG subclass-independent improvement of
antibody-dependent cellular cytotoxicity by fucose removal from
Asn297-linked oligosaccharides. J Immunol Methods 2005;
306:151-60; PMID:16219319; http://dx.doi.org/10.1016/j.
jim.2005.08.009
ONCOIMMUNOLOGY e1294296-9
85. Warncke M, Calzascia T, Coulot M, Balke N, Touil R, Kolbinger F,
Heusser C. Different adaptations of IgG effector function in human
and nonhuman primates and implications for therapeutic antibody
treatment. J Immunol 2012; 188:4405-11; PMID:22461693; http://dx.
doi.org/10.4049/jimmunol.1200090
86. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR.
Optimization of antibody binding to FcgammaRIIa enhances macro-
phage phagocytosis of tumor cells. Mol Cancer Ther 2008; 7:2517-
27; PMID:18723496; http://dx.doi.org/10.1158/1535-7163.MCT-08-
0201
87. Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-
dependent cellular cytotoxicity in tumor immunotherapy with thera-
peutic antibodies. Front Immunol 2013; 4:76; PMID:23543707;
http://dx.doi.org/10.3389/ﬁmmu.2013.00076
88. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker
WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J
et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with
endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71;
PMID:19620983; http://dx.doi.org/10.1038/nbt.1553
89. Davies AM, Rispens T, den Bleker TH, McDonnell JM, Gould HJ,
Aalberse RC, Sutton BJ. Crystal structure of the human IgG4 C(H)3
dimer reveals the role of Arg409 in the mechanism of Fab-arm
exchange. Mol Immunol 2013; 54:1-7; PMID:23164605; http://dx.
doi.org/10.1016/j.molimm.2012.10.029
90. Davies AM, Rispens T, Ooijevaar-de Heer P, Gould HJ, Jefferis R,
Aalberse RC, Sutton BJ. Structural determinants of unique properties
of human IgG4-Fc. J Mol Biol 2014; 426:630-44; PMID:24211234;
http://dx.doi.org/10.1016/j.jmb.2013.10.039
91. Crescioli S, Correa I, Karagiannis P, Davies AM, Sutton BJ, Nestle
FO, Karagiannis SN. IgG4 characteristics and functions in cancer
immunity. Curr Allergy Asthma Rep 2016; 16:7; PMID:26742760;
http://dx.doi.org/10.1007/s11882-015-0580-7
92. Karagiannis P, Villanova F, Josephs DH, Correa I, Van Hemelrijck
M, Hobbs C, Saul L, Egbuniwe IU, Tosi I, Ilieva KM et al. Elevated
IgG4 in patient circulation is associated with the risk of disease pro-
gression in melanoma. Oncoimmunology 2015; 4:e1032492;
PMID:26451312; http://dx.doi.org/10.1080/2162402X.2015.1032492
93. Aleyd E, Heineke MH, van Egmond M. The era of the immunoglob-
ulin A Fc receptor FcaRI; its function and potential as target in dis-
ease. Immunol Rev 2015; 268:123-38; PMID:26497517; http://dx.doi.
org/10.1111/imr.12337
94. Rodrıguez-Pinto D. B cells as antigen presenting cells. Cell Immunol
2005; 238:67-75; PMID:16574086; http://dx.doi.org/10.1016/j.
cellimm.2006.02.005
95. Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as
antigen-presenting cells in vivo revisited: antigen-speciﬁc B cells are
essential for T cell expansion in lymph nodes and for systemic T cell
responses to low antigen concentrations. Int Immunol 2001;
13:1583-93; PMID:11717199; http://dx.doi.org/10.1093/intimm/
13.12.1583
96. Von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N,
Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW,
Nadler LM et al. Human primary and memory cytotoxic T lympho-
cyte responses are efﬁciently induced by means of CD40-activated B
cells as antigen-presenting cells: potential for clinical application.
Blood 2002; 99:3319-25; PMID:11964299; http://dx.doi.org/10.1182/
blood.V99.9.3319
97. Becker HJ, Kondo E, Shimabukuro-Vornhagen A, Theurich S, von
Bergwelt-Baildon MS. Processing and MHC class II presentation of
exogenous soluble antigen involving a proteasome-dependent cyto-
solic pathway in CD40-activated B cells. Eur J Haematol 2016;
97:166-74; PMID:26561366; http://dx.doi.org/10.1111/ejh.12699
98. Lanzavecchia A. Antigen-speciﬁc interaction between T and B cells.
Nature 1985; 314:537-9; PMID:3157869; http://dx.doi.org/10.1038/
314537a0
99. Fillatreau S. Cytokine-producing B cells as regulators of pathogenic
and protective immune responses. Ann Rheum Dis 2013; 72 Suppl 2:
ii80-4; PMID:23253921; http://dx.doi.org/10.1136/annrheumdis-
2012-202253
100. Vazquez MI, Catalan-Dibene J, Zlotnik A. B cells responses and cyto-
kine production are regulated by their immune microenvironment.
Cytokine 2015; 74:318-26; PMID:25742773; http://dx.doi.org/
10.1016/j.cyto.2015.02.007
101. Duddy ME, Alter A, Bar-Or A. Distinct proﬁles of human B cell
effector cytokines: a role in immune regulation? J Immunol
2004; 172:3422-7; PMID:15004141; http://dx.doi.org/10.4049/
jimmunol.172.6.3422
102. Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim
HJ, Bar-Or A. Distinct effector cytokine proﬁles of memory and
naive human B cell subsets and implication in multiple sclerosis. J
Immunol 2007; 178:6092-9; PMID:17475834; http://dx.doi.org/
10.4049/jimmunol.178.10.6092
103. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, Lepak NM,
Johnson LL, Swain SL, Lund FE. Reciprocal regulation of polarized
cytokine production by effector B and T cells. Nat Immunol 2000;
1:475-82; PMID:11101868; http://dx.doi.org/10.1038/82717
104. Sarwal M, Chua MS, Kambham N, Hsieh SC, Satterwhite T, Masek
M, Salvatierra O. Molecular heterogeneity in acute renal allograft
rejection identiﬁed by DNA microarray proﬁling. N Engl J Med
2003; 349:125-38; PMID:12853585; http://dx.doi.org/10.1056/
NEJMoa035588
105. Zarkhin V, Kambham N, Li L, Kwok S, Hsieh SC, Salvatierra O, Sar-
wal MM. Characterization of intra-graft B cells during renal allograft
rejection. Kidney Int 2008; 74:664-73; PMID:18547992; http://dx.doi.
org/10.1038/ki.2008.249
106. Lapointe R, Bellemare-Pelletier A, Housseau F, Thibodeau J, Hwu P.
CD40-stimulated B lymphocytes pulsed with tumor antigens are
effective antigen-presenting cells that can generate speciﬁc T cells.
Cancer Res 2003; 63:2836-43; PMID:12782589
107. Tao H, Lu L, Xia Y, Dai F, Wang Y, Bao Y, Lundy SK, Ito F, Pan Q,
Zhang X et al. Antitumor effector B cells directly kill tumor cells via
the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol
2015; 45:999-1009; PMID:25545618; http://dx.doi.org/10.1002/
eji.201444625
108. Xia Y, Tao H, Hu Y, Chen Q, Chen X, Xia L, Zhou L, Wang Y, Bao Y,
Huang S et al. IL-2 augments the therapeutic efﬁcacy of adoptively
transferred B cells which directly kill tumor cells via the CXCR4/
CXCL12 and perforin pathways. Oncotarget 2016; 37:60461-74;
PMID:27528023; http://dx.doi.org/10.18632/oncotarget.11124
109. Aklilu M, Stadler WM, Markiewicz M, Vogelzang NJ, Mahowald M,
Johnson M, Gajewski TF. Depletion of normal B cells with rituximab
as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
Ann Oncol 2004; 15:1109-14; PMID:15205206; http://dx.doi.org/
10.1093/annonc/mdh280
110. Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K,
Kurschat P, Rabenhorst A, Hartmann K, Schl€osser H, Shimabukuro-
Vornhagen A et al. Targeting tumor-inﬁltrating B cells in cutaneous
T-cell lymphoma. J Clin Oncol 2016; 34:e110-6; PMID:25348001;
http://dx.doi.org/10.1200/JCO.2013.50.9471
111. Pinc A, Somasundaram R, Wagner C, H€ormann M, Karanikas G,
Jalili A, Bauer W, Brunner P, Grabmeier-Pﬁstershammer K,
Gschaider M et al. Targeting CD20 in melanoma patients at high
risk of disease recurrence. Mol Ther 2012; 20:1056-62;
PMID:22354376; http://dx.doi.org/10.1038/mt.2012.27
112. Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch
MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A,
von Bergwelt-Baildon MS. CD40-activated B cells can be generated
in high number and purity in cancer patients: analysis of immunoge-
nicity and homing potential. Clin Exp Immunol 2009; 155:249-56;
PMID:19040609; http://dx.doi.org/10.1111/j.1365-2249.2008.03820.x
113. Coughlin CM, Vance BA, Grupp SA, Vonderheide RH. RNA-trans-
fected CD40-activated B cells induce functional T-cell responses
against viral and tumor antigen targets: implications for pediatric
immunotherapy. Blood 2004; 103:2046-54; PMID:14630810; http://
dx.doi.org/10.1182/blood-2003-07-2379
114. Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE.
Adoptive transfer of tumor reactive B cells confers host T-cell
immunity and tumor regression. Clin Cancer Res 2011; 17:4987-
e1294296-10 G. CHIARUTTINI ET AL.
95; PMID:21690573; http://dx.doi.org/10.1158/1078-0432.CCR-
11-0207
115. Ebstein F, Keller M, Paschen A, Walden P, Seeger M, B€urger E,
Kr€uger E, Schadendorf D, Kloetzel PM, Seifert U. Exposure to
Melan-A/MART-126-35 tumor epitope speciﬁc CD8(C)T cells
reveals immune escape by affecting the ubiquitin-proteasome system
(UPS). Sci Rep 2016; 6:25208; PMID:27143649; http://dx.doi.org/
10.1038/srep25208
116. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic b-catenin sig-
nalling prevents anti-tumour immunity. Nature 2015; 523:231-5;
PMID:25970248; http://dx.doi.org/10.1038/nature14404
117. Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodri-
guez-Cruz T, Liu S, Whittington M, Deng W, Li F et al.
BRAFV600E co-opts a conserved MHC class I internalization
pathway to diminish antigen presentation and CD8C T-cell
recognition of melanoma. Cancer Immunol Res 2015; 3:602-9;
PMID:25795007; http://dx.doi.org/10.1158/2326-6066.
CIR-15-0030
118. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff
K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD et al. Fc-
dependent depletion of tumor-inﬁltrating regulatory T cells co-
deﬁnes the efﬁcacy of anti-CTLA-4 therapy against melanoma. J
Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/
10.1084/jem.20130579
119. Josephs DH, Spicer JF, Karagiannis P, Gould HJ, Karagiannis SN. IgE
immunotherapy: a novel concept with promise for the treatment of
cancer. MAbs 2014; 6:54-72; PMID:24423620; http://dx.doi.org/
10.4161/mabs.27029
ONCOIMMUNOLOGY e1294296-11
